Nottingham researchers win joint Queen's Award
Nottingham university’s school of pharmacy and its spin-off
company recognised as innovators |
The University of Nottingham School of Pharmacy and Molecular Profiles, a spin-off company from the university, have received a joint innovation award in the Queen's
Awards for Enterprise.
The Co-operative Group, which includes the Co-operative Pharmacy, is
also recognised in the awards. The business received the sustainable
development award.
The school of pharmacy and Molecular Profiles — set up as a spin-off
in 1997 — are recognised in the continuous innovation and development
category for their approach to the analysis of pharmaceuticals using
nanotechnology-based methods.
A spokesman for the Queen’s Awards office described the school
as an internationally recognised centre of excellence in nanotechnology
research.
“This research is producing exciting breakthrough results. The school
is enhancing significantly the development of new medicines,” he
added.
Molecular Profiles develops novel applications based around advanced
surface analysis and nanotechnologies to provide an insight into the
chemical, physical and material properties of pharmaceutical and biomedical
products.
Its services include nanoscreening technology for predicting the ease
of development of a new medicine, a deformulation service for pin-pointing
product problems down to the nanoscale and advanced imaging for viewing
and optimising the internal structure of products.
Nikin Patel, Molecular Profiles chief executive officer, said: “Our
services and technology are extremely innovative but it is our scientists
who develop the rapid response solutions that solve our customers’ challenges.
This award recognises their expertise and commitment in making Molecular
Profiles a cutting edge global contract research
company.”
Martyn Davies, chairman and a founder of Molecular Profiles and professor
of biomedical surface chemistry at the school of pharmacy, added: “Our
company was founded on innovation and I am proud to say that ethos has
remained as the company has grown successfully over the last 10 years.” |
The
Pharmaceutical Journal
Acrobat
Reader